Skip to main content Accessibility help
×
Home
  • Cited by 2
  • Print publication year: 2011
  • Online publication date: August 2011

23 - Movement disorders in neurometabolic diseases

Related content

Powered by UNSILO

References

1. Jinnah HA, Visser JE, Harris JC et al. Delineation of the motor disorder of Lesch–Nyhan disease. Brain 2006 May; 129(Pt 5): 1201–17.
2. Roze E, Paschke E, Lopez N et al. Dystonia and parkinsonism in GM1 type 3 gangliosidosis. Mov Disord 2005; 20(10): 1366–9.
3. Gitiaux C, Roze E, Kinugawa K et al. Spectrum of movement disorders associated with glutaric aciduria type 1: a study of 16 patients. Mov Disord 2008; 23(16): 2392–7.
4. Ala A, Walker AP, Ashkan K, Dooley JS, Schilsky ML. Wilson’s disease. Lancet 2007; 369(9559): 397–408.
5. Machado A, Chien HF, Deguti MM et al. Neurological manifestations in Wilson’s disease: report of 119 cases. Mov Disord 2006; 21(12): 2192–6.
6. Sinha S, Taly AB, Ravishankar S et al. Wilson’s disease: cranial MRI observations and clinical correlation. Neuroradiology 2006; 48(9): 613–21.
7. Gregory A, Polster BJ, Hayflick SJ. Clinical and genetic delineation of neurodegeneration with brain iron accumulation. J Med Genet. 2009; 46(2): 73–80.
8. Hayflick SJ. Unraveling the Hallervorden–Spatz syndrome: pantothenate kinase-associated neurodegeneration is the name. Curr Opin Pediatr 2003; 15(6): 572–7.
9. Pellecchia MT, Valente EM, Cif L et al. The diverse phenotype and genotype of pantothenate kinase-associated neurodegeneration. Neurology 2005; 64(10): 1810–2.
10. Hartig MB, Hortnagel K, Garavaglia B et al. Genotypic and phenotypic spectrum of PANK2 mutations in patients with neurodegeneration with brain iron accumulation. Ann Neurol 2006; 59(2): 248–56.
11. Freeman K, Gregory A, Turner A, Blasco P, Hogarth P, Hayflick S. Intellectual and adaptive behaviour functioning in pantothenate kinase-associated neurodegeneration. J Intellect Disabil Res 2007; 51(Pt 6): 417–26.
12. Kurian MA, Morgan NV, MacPherson L et al. Phenotypic spectrum of neurodegeneration associated with mutations in the PLA2G6 gene (PLAN). Neurology 2008; 70(18): 1623–9.
13. McNeill A, Birchall D, Hayflick SJ et al. T2* and FSE MRI distinguishes four subtypes of neurodegeneration with brain iron accumulation. Neurology 2008; 70(18): 1614–9.
14. Gregory A, Westaway SK, Holm IE et al. Neurodegeneration associated with genetic defects in phospholipase A(2). Neurology 2008; 71(18): 1402–9.
15. Paisan-Ruiz C, Bhatia KP, Li A et al. Characterization of PLA2G6 as a locus for dystonia-parkinsonism. Ann Neurol 2009; 65(1): 19–23.
16. Chinnery PF, Crompton DE, Birchall D et al. Clinical features and natural history of neuroferritinopathy caused by the FTL1 460InsA mutation. Brain 2007; 130(Pt 1): 110–9.
17. McNeill A, Pandolfo M, Kuhn J, Shang H, Miyajima H. The neurological presentation of ceruloplasmin gene mutations. Eur Neurol 2008; 60(4): 200–5.
18. Aamodt AH, Stovner LJ, Thorstensen K, Lydersen S, White LR, Aasly JO. Prevalence of haemochromatosis gene mutations in Parkinson’s disease. J Neurol Neurosurg Psychiatry 2007; 78(3): 315–7.
19. Dekker MC, Giesbergen PC, Njajou OT et al. Mutations in the hemochromatosis gene (HFE), Parkinson’s disease and parkinsonism. Neurosci Lett 2003; 348(2): 117–9.
20. Demarquay G, Setiey A, Morel Y, Trepo C, Chazot G, Broussolle E. Clinical report of three patients with hereditary hemochromatosis and movement disorders. Mov Disord 2000; 15(6): 1204–9.
21. Pearl PL, Capp PK, Novotny EJ, Gibson KM. Inherited disorders of neurotransmitters in children and adults. Clin Biochem 2005; 38(12): 1051–8.
22. Manegold C, Hoffmann GF, Degen I et al. Aromatic l-amino acid decarboxylase deficiency: clinical features, drug therapy and follow-up. J Inherit Metab Dis 2009; 32(3): 371–80.
23. Clot F, Grabli D, Cazeneuve C et al. Exhaustive analysis of BH4 and dopamine biosynthesis genes in patients with dopa-responsive dystonia. Brain 2009; 132(Pt 7): 1753–63.
24. Trender-Gerhard I, Sweeney MG et al. Autosomal-dominant GTPCH1-deficient DRD: clinical characteristics and long-term outcome of 34 patients. J Neurol Neurosurg Psychiatry 2009; 80(8): 839–45.
25. Ozand PT, Gascon GG, Al Essa M et al. Biotin-responsive basal ganglia disease: a novel entity. Brain 1998; 121(Pt 7): 1267–79.
26. Bindoff LA, Birch-Machin MA, Farnsworth L, Gardner-Medwin D, Lindsay JG, Turnbull DM. Familial intermittent ataxia due to a defect of the E1 component of pyruvate dehydrogenase complex. J Neurol Sci 1989; 93(2–3): 311–8.
27. Head RA, de Goede CG, Newton RW et al. Pyruvate dehydrogenase deficiency presenting as dystonia in childhood. Dev Med Child Neurol 2004; 46(10): 710–2.
28. Brockmann K. The expanding phenotype of GLUT1-deficiency syndrome. Brain Dev 2009; 31(7): 545–52.
29. Schneider SA, Paisan-Ruiz C, Garcia-Gorostiaga I et al. GLUT1 gene mutations cause sporadic paroxysmal exercise-induced dyskinesias. Mov Disord 2009; 24(11): 1684–8.
30. Suls A, Dedeken P, Goffin K et al. Paroxysmal exercise-induced dyskinesia and epilepsy is due to mutations in SLC2A1, encoding the glucose transporter GLUT1. Brain 2008; 131(Pt 7): 1831–44.
31. Macaya A, Munell F, Burke RE, De Vivo DC. Disorders of movement in Leigh syndrome. Neuropediatrics 1993; 24(2): 60–7.
32. Yamamoto M, Ujike H, Wada K, Tsuji T. Cerebrospinal fluid lactate and pyruvate concentrations in patients with Parkinson’s disease and mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS). J Neurol Neurosurg Psychiatry 1997; 62(3): 290.
33. Luoma PT, Eerola J, Ahola S et al. Mitochondrial DNA polymerase gamma variants in idiopathic sporadic Parkinson disease. Neurology 2007; 69(11): 1152–9.
34. Oates CE, Bosch EP, Hart MN. Movement disorders associated with chronic GM2 gangliosidosis. Case report and review of the literature. Eur Neurol 1986; 25(2): 154–9.
35. Nardocci N, Bertagnolio B, Rumi V, Angelini L. Progressive dystonia symptomatic of juvenile GM2 gangliosidosis. Mov Disord 1992; 7(1): 64–7.
36. Sevin M, Lesca G, Baumann N et al. The adult form of Niemann–Pick disease type C. Brain 2007; 130(Pt 1): 120–33.
37. Berkovic SF, Carpenter S, Andermann F, Andermann E, Wolfe LS. Kufs’ disease: a critical reappraisal. Brain 1988; 111(Pt 1): 27–62.
38. Nijssen PC, Brusse E, Leyten AC, Martin JJ, Teepen JL, Roos RA. Autosomal dominant adult neuronal ceroid lipofuscinosis: parkinsonism due to both striatal and nigral dysfunction. Mov Disord 2002; 17(3): 482–7.
39. Federico A, Battistini S, Ciacci G et al. Cherry-red spot myoclonus syndrome (type I sialidosis). Dev Neurosci 1991; 13(4–5): 320–6.
40. Neumann J, Bras J, Deas E et al. Glucocerebrosidase mutations in clinical and pathologically proven Parkinson’s disease. Brain 2009; 132(Pt 7): 1783–94.
41. Ceballos-Picot I, Mockel L, Potier MC et al. Hypoxanthine-guanine phosphoribosyl transferase regulates early developmental programming of dopamine neurons: implications for Lesch–Nyhan disease pathogenesis. Hum Mol Genet 2009 1; 18(13): 2317–27.
42. Schretlen DJ, Ward J, Meyer SM et al. Behavioral aspects of Lesch–Nyhan disease and its variants. Dev Med Child Neurol 2005; 47(10): 673–7.
43. Adam OR, Jankovic J. Treatment of dystonia. Parkinsonism Relat Disord 2007; 13(Suppl 3): S362–8.
44. Vidailhet M, Vercueil L, Houeto JL et al. Bilateral deep-brain stimulation of the globus pallidus in primary generalized dystonia. N Engl J Med 2005; 352(5): 459–67.
45. Kupsch A, Benecke R, Muller J et al. Pallidal deep-brain stimulation in primary generalized or segmental dystonia. N Engl J Med 2006; 355(19): 1978–90.
46. Vidailhet M, Yelnik J, Lagrange C et al. Bilateral pallidal deep brain stimulation for the treatment of patients with dystonia-choreoathetosis cerebral palsy: a prospective pilot study. Lancet Neurol 2009; 8(8): 709–17.
47. Mikati MA, Yehya A, Darwish H, Karam P, Comair Y. Deep brain stimulation as a mode of treatment of early onset pantothenate kinase-associated neurodegeneration. Eur J Paediatr Neurol 2009; 13(1): 61–4.
48. Roze E, Navarro S, Cornu P, Welter ML, Vidailhet M. Deep brain stimulation of the globus pallidus for generalized dystonia in GM1 Type 3 gangliosidosis: technical case report. Neurosurgery 2006; 59(6): E1340; discussion E.
49. Aniello MS, Martino D, Petruzzella V et al. Bilateral striatal necrosis, dystonia and multiple mitochondrial DNA deletions: case study and effect of deep brain stimulation. Mov Disord 2008; 23(1): 114–8.
50. Cif L, Biolsi B, Gavarini S, et al. Antero-ventral internal pallidum stimulation improves behavioral disorders in Lesch–Nyhan disease. Mov Disord 2007; 22(14): 2126–9.